1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (use ribavirin)
3TC (see also lamivudine) - June, p. 170; Aug., p. 227, 236; Sep., p. 262; Dec., p. 363
3TC plus AZT - Feb., p. 35; Aug., p. 227; Nov., p. 321
5-fluorouracil gel - Feb., p. 46; Sep., p. 264; Dec., p. 364
9-(2-phosphonylmethoxyethyl)adenine, bis pivaloyoxylmethyl- - May, p. 132
[9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine], diacetyl ester - May, p. 138
ABT-538 (use ritonavir)
AccuSite Injectable Gel - Feb., p. 46; Sep., p. 264; Dec., p. 364
acemannan - Aug., p. 236
acetylsalicylic acid - Apr., p. 105
acyclovir - Feb., p. 40; Apr., p. 101; May, p. 135; Oct., p. 294
acyclovir, cream - Oct., p. 293
acyclovir, over-the-counter - Feb., p. 36; Dec., p. 363
AD-439 - July, p. 197
AD-519 - July, p. 197
adenine, (R)-9-(2-phosphonylmethoxypropyl)- - Nov., p. 325
adenovirus gene therapy vectors - Oct., p. 298
AG1343 - Feb., p. 37; May, p. 137; Aug., p. 232; Sep., p. 266; Oct., p. 298
Alferon N Gel - June, p. 169
Alferon N Injection - Feb., p. 46; May, p. 139
ALVAC-HIV (vCP205) - June, p. 164
ALX40-4C - Feb., p. 40; Oct., p. 299
amantadine - Feb., p. 43
anabolic steroids - June, p. 171
antisense oligonucleotides - Feb., p. 41; Apr., p. 102; May, p. 131; June, p. 171; July, p. 206; Oct., p. 293; Nov., p. 332
AR-121 - Mar., p. 75; Nov., p. 325
AR132 - Nov., p. 333
AR177 - Nov., p. 325; Nov., p. 333
aspirin - Apr., p. 105
AZT - Mar., p. 76; Apr., p. 103; June, p. 171, 173; July, p. 195; Sep., p. 257, 264, 266; Oct., p. 290, 291; Dec., p. 363
AZT, controlled release (Aztec) - Apr., p. 102; Dec., p. 365
AZT, generic - Apr., p. 105
AZT-DDI dimer - Feb., p. 42
AZT plus DDC - Oct., p. 289
AZT plus DDI - Oct., p. 289
baboon bone marrow transplants - May, p. 140; Aug., p. 230
BCX-140 - Feb., p. 41
beta-propriolactone - Feb., p. 40
bichloroacetic acid - Oct., p. 296
BioLogic-HT System - May, p. 138
bis(POM)PMEA - May, p. 132
bovine peptide-nucleic acid solution - Feb., p. 43
Bucast - May, p. 139; Nov., p. 328
bupivacaine - Aug., p. 231
calanolide A - Oct., p. 300
canine oral papillomavirus vaccines - Dec., p. 360
CD4+/CD8+ T-cell monitoring systems - Sep., p. 267
CD4-based polypeptide - May, p. 134
CD4-Immunoglobulin G2 (CD4-IgG2) - June, p. 166
Cell Production System (CPS) - Nov., p. 330
cell antiviral factor (CAF) - Dec., p. 358
chemokines - Dec., p. 358
chickenpox vaccines - Apr., p. 104; July, p. 204
Chinese medicinal herbs - Dec., p. 366
cidofovir prodrug - May, p. 133
cidofovir - Feb., p. 38; May, p. 133; Sep., p. 260; Oct., p. 292
cidofovir, intravitreal - May, p. 133; Sep., p. 260
CMV antisense oligonucleotides - May, p. 131; Oct., p. 293
CMV gH humanized monoclonal antibody - Nov., p. 327
CMV vaccines - Sep., p. 260; Oct., p. 292
condyloma acuminata vaccine - Oct., p. 296
Condylox - Apr., p. 105
Croton lechleri - June, p. 162
curcumin - July, p. 205
cyclodepsipeptides - May, p. 136
cytolin - Oct., p. 297
cytotoxic T-lymphocytes, autologous transfer - June, p. 165
Cytovene (use ganciclovir)
D4T - May, p. 130; Aug., p. 236; Nov., p. 331
DDC - Apr., p. 103; Sep., p. 257, 264; Oct., p. 290; Dec., p. 363
DDI - June, p. 168; Sep., p. 257, 263; Dec., p. 363
DDI plus AZT - Mar., p. 76; Sep., p. 257
dehydrodidemnin A - May, p. 136
deoxyribonucleic guanidine (DNG) - June, p. 171
didemnins - May, p. 136
dideoxyadenosine, 2'-fluoro-2',3'- - Feb., p. 46
dideoxyinosine, 2'-fluoro-2',3'- - Feb., p. 46
dideoxythymidine, 2',3'-didehydro-2',3'- (use D4T)
Disabled Infectious Single Cycle (DISC) vaccines - Oct., p. 301
DMP-450 - Mar., p. 72
DP-178 - Oct., p. 300
E. coli enterotoxin adjuvants - Oct., p. 302
Ebola virus immune globulins - Sep., p. 267; Dec., p. 361
Engerix-B - Apr., p. 109
Epivir (use 3TC)
Eukaryotic Layered Vector System - Apr., p. 98
F-ddA - Feb., p. 46
F-ddI - Feb., p. 46
F105 antibody - July, p. 198
F58/A3 - July, p. 198
famciclovir - May, p. 138; Oct., p. 297; Dec., p. 355
Famvir (use famciclovir)
Fas/CD95 - Nov., p. 333
fialuridine (FIAU) - Mar., p. 76
foscarnet sodium - July, p. 193; Sep., p. 266
Foscavir (use foscarnet sodium)
furyl epoxy ketones - May, p. 136
ganciclovir - Feb., p. 42; Sep. 266, 267
ganciclovir, implant - Feb., p. 39; July, p. 202; Dec., p. 357
ganciclovir, oral - Feb., p. 33; May, p. 139; Oct., p. 295; Nov., p. 324
GEM 91 - Feb., p. 41
gene therapy, ex vivo - Apr., p. 107; July, p. 199
gene therapy, HIV-activated T-cells - Sep., p. 265; Nov., p. 328
gene therapy, HIV-infection - Nov., p. 330; Dec., p. 361
Gene-Modified Oligonucleotides (GMOs) - Nov., p. 332
GENEVAX vaccines - Aug., p. 231; Dec., p. 361
Geomatrix technology - Apr., p. 102
GS 504 (use cidofovir)
GS 840 - May, p. 132
GS 930 - May, p. 133
GS-1278 - Nov., p. 325
guanine-thymine oligonucleotides - Nov., p. 325
H-BIG - Sep., p. 260, 267
Havrix - Feb., p. 42; Mar., p. 67; Aug., p. 236
HBY 097 - Nov., p. 328
hepatitis A vaccines - Feb., p. 42; Mar., p. 67; May, p. 129; Aug., p. 236
hepatitis B drugs - Sep., p. 265
hepatitis B gene therapy - Feb., p. 46; Apr., p. 98
hepatitis B immune globulin - Sep., p. 260, 267
hepatitis B peptide/MHC receptor vaccines - Nov., p. 330
hepatitis B reverse transcriptase inhibitors - Apr., p. 109
hepatitis B virus vaccines - Apr., p. 109; June, p. 171
hepatitis C drugs - Sep., p. 265
hepatitis C virus diagnostics - May, p. 141; Nov., p. 335; Dec., p. 366
hepatitis C virus vaccines - Mar., p. 77; May, p. 142
hepatitis G virus vaccines - Feb., p. 38; Mar., p. 77; May, p. 142
HGP-30 - Apr., p. 102; May, p. 140; Aug., p. 235; Oct., p. 299; Nov., p. 331
HIV antisense oligonucleotides - Feb., p. 41
HIV apoptosis inhibitors - May, p. 136
HIV diagnostics - May, p. 142; July, p. 205; Sep., p. 269
HIV drug combinations - Oct., p. 300
HIV envelope peptide vaccines - June, p. 170
HIV gene therapy vaccines - Apr., p. 98; Sep., p. 265; Oct., p. 296; Nov., p. 328, 330; Dec., p. 361
HIV glycoproteins - Oct., p. 302
HIV glycosidase inhibitors - May, p. 139; Nov., p. 328
HIV gp120 monoclonal antibodies - July, p. 197, 198
HIV gp120 peptides - July, p. 201
HIV gp160 vaccines - May, p. 137
HIV gp41 vaccines - Oct., p. 300
HIV immune globulins - Feb., p. 40; July, p. 198; Sep., p. 260
HIV Immunotherapeutic - Feb., p. 37; Mar., p. 74; June, p. 170; Oct., p. 298
HIV integrase inhibitors - Nov., p. 325, 333
HIV neutralizing antibodies - Nov., p. 328
HIV p17 vaccines - Apr., p. 102; May, p. 140; Aug., p. 235; Oct., p. 299; Nov., p. 331
HIV p17/p24:Ty-VLP vaccines - July, p. 197
HIV p45 and p80 - Dec., p. 364
HIV p7 nucleoprotein - Apr., p. 109
HIV peptide/MHC receptor vaccines - Oct., p. 300; Nov., p. 330
HIV protease inhibitors - Feb., p. 37; Mar., p. 72, 73; May, p. 137, 140; Aug., p. 232, 233, 235; Oct., p. 290, 291, 298; 299; Nov., p. 323; Dec., p. 353; 356
HIV protein-tyrosine kinase inhibitors - Dec., p. 366
HIV Tat inhibitors - Feb., p. 40; Oct., p. 299
HIV tyrosine kinase inhibitors - July, p. 202
HIV Universal Antiviral Binding technology - June, p. 166
HIV vaccines - July, p. 196; Nov., p. 331, 333; Dec., p. 364
HIV vaccines, canarypox virus vectors - June, p. 164
HIV vaccines, inactivated core - Feb., p. 37; Mar., p. 74; June, p. 170; Oct., p. 298
HIV vaccines, live - Feb., p. 42; May, p. 131; July, p. 203
HIV vaccines, prophylactic - June, p. 172
HIV zinc finger inhibitors - Aug., p. 238
HIV-1 envelope/beta-galactosidase vaccines - Sep., p. 260
HIV-1 gp120 C4-V3 peptide vaccines - Sep., p. 262
HIV-2 live vaccines - July, p. 194
HIV-infected cell apoptosis inducers - July, p. 202
HIV-IT (V) - Apr., p. 98; Oct., p. 296
HIVase-1 - Apr., p. 99
HIVID (use DDC)
HIVIG - Sep., p. 260
HNK20 - Oct., p. 294
HPMPC (use cidofovir)
HPV drugs - June, p. 163
HPV enzyme inhibitors - Apr., p. 103
HPV gene therapy vaccines - Dec., p. 361
HPV vaccines - Feb., p. 41; June, p. 163; Oct., p. 296; Nov., p. 335; Dec., p. 360
HSV gD vaccines - Sep., p. 260
HSV gD2 gene therapy vaccines - Dec., p. 361
HTLV-I diagnostics - Sep., p. 266
Human Anti-Cytomegalovirus Antibody - Nov., p. 327
human growth hormone, recombinant - Feb., p. 42
hydroxyurea - Sep., p. 263
hypericin - Apr., p. 104; May, p. 139
hyperthermia, extracorporeal - May, p. 138
Immupath - Feb., p. 40
indinavir sulfate - Mar., p. 72, 73; Aug., p. 233; Oct., p. 291, 298; Dec., p. 362
Infergen - Aug., p. 233; Nov., p. 330
influenza A virus, naked DNA vaccines - July, p. 203
influenza vaccines - Oct., p. 299; Apr., p. 108, 109; May, p. 138; June, p. 164, 169; Oct., p. 299; Nov., p. 330, 331; Dec., p. 363
interferon alfa-n3 - Feb., p. 46; May, p. 139; June, p. 169; Dec., p. 360
interferon, alpha-2a - May, p. 139; June, p. 171
interferon, alpha-2b - May, p. 139; Aug., p. 234
interferon, beta - Apr., p. 104; May, p. 135
interferon-alpha, concensus - Aug., p. 233; Nov., p. 330
interferon-alpha, injection - Oct., p. 296
interferon-alpha, oral - Nov., p. 331
interleukin-12 (IL-12) - July, p. 200; Oct., p. 298; Nov., p. 329
interleukin-16 (IL-16) - Dec., p. 358
interleukin-2 (IL-2) gene therapy - Sep., p. 270
interleukin-2 (IL-2) - Mar., p. 70; Sep., p. 279; Oct., p. 291
intracellular adhesion molecule-1 (ICAM-1) - Oct., p. 295
Intron A (use interferon, alpha-2b)
Invirase (use saquinavir)
ISIS 2922 - May, p. 131; Oct., p. 293
ISIS 5320 - Nov., p. 335
KNI-272 - Mar., p. 72
L-735,524 (use indinavir sulfate)
lamivudine (see also 3TC) - Aug., p. 227; Nov., p. 326, 334
LeukoVir-MB Filter - Nov., p. 331
Lidakol, intravaginal - May, p. 137, 138; Oct., p. 293
liposomal vaccine adjuvant - Apr., p. 109
lymphocyte LFA-1 monoclonal antibodies - Oct., p. 297
marine drugs - May, p. 136; Aug., p. 236
MEDI-491 - Apr., p. 97
MEDI-493 - Nov., p. 327
methylene blue dye - Nov., p. 331
MF59 - Oct., p. 292
MIP1-alpha - Dec., p. 358
MIP1-beta - Dec., p. 358
MK-639 (use indinavir sulfate)
monophosphoryl lipid A - Oct., p. 299
MSL-109 - Nov., p. 327
n-docosanol (use Lidakol)
naphthalene sulfonates - May, p. 134
Natural Alpha Interferon - Dec., p. 360
nevirapine - Apr., p. 103; Dec., p. 362, 363
nucleic acid sequence based amplification (NASBA) - Dec., p. 366
nystatin, liposomal - Mar., p. 75; Nov., p. 325
oligonucleotides, Zyn-Linker derivatives - Dec., p. 364
Optivax System - Sep., p. 270; Nov., p. 335
OraSure saliva collection devices - May, p. 142
parvovirus B19 virus-like particle vaccine - Apr., p. 97
Peptide T - Nov., p. 329
phosphonoformic acid, trisodium salt (use foscarnet sodium)
photoinactivation, blood - Sep., p. 270
PIC 024 - May, p. 134
PM92131 - May, p. 136
PMPA - Nov., p. 325
PN355 - July, p. 202; Dec., p. 366
podophyllin - Oct., p. 296
podophyllotoxin - Apr., p. 105
polycationic DNA analogs - June, p. 171
PRO 542 - June, p. 166
PRO 2000 - May, p. 134
proanthocyanidin polyphenolic oligomer - June, p. 162
Proleukin (use interleukin-2)
Proteinoid Oral Drug Delivery System - June, p. 169; Nov., p. 331
ProVax - Nov., p. 333; Dec., p. 364
Provir - June, p. 162
QS-21 Stimulon - Sep., p. 260; Oct., p. 299
RANTES - Dec., p. 358
RBC-CD4 - Aug., p. 235
RespiGam (use RSVIG-IV)
respiratory syncytial virus immune globulin-intravenous (use RSVIG-IV)
Reticulose - Feb., p. 43
Retrovir (use AZT)
ribavirin - Mar., p. 75; Aug., p. 234
ribonucleic guanidine - June, p. 171
ribozyme gene therapy - Mar., p. 76; Apr., p. 99
rimantadine - Feb., p. 43
ritonavir - Oct., p. 290, 298; Dec., p. 362, 364
Roferon A (use interferon, alpha-2a)
rotavirus vaccines, live oral - Apr., p. 100
RSV monoclonal antibodies - Oct., p. 294; Nov., p. 327
RSV vaccines - Nov., p. 327
RSVIG-IV - June, p. 168; Aug., p. 228; Nov., p. 327; Dec., p. 364
saliva, anti-HIV proteins - May, p. 136
saquinavir - Mar., p. 72; Apr., p. 103; June, p. 161; July, p. 195, 203; Aug., p. 235; Sep., p. 264; Oct., p. 290, 298; Nov., p. 323; Dec., p. 353
Scriptene - Feb., p. 42
secretory leukocyte protease inhibitor (SLPI) - May, p. 136
Serostim (use human growth hormone, recombinant)
single-chain antibody fusion protein immunotoxins - Mar., p. 75
SIV BCG vector vaccines - Nov., p. 333
SIV vaccine, live attenuated (SIVĘ3) - May, p. 133
SMART antibodies - Nov., p. 327
solvent/detergent inactivation - Apr., p. 105
SP-303 (use Provir)
SPC3 - July, p. 201
stavudine (use D4T)
systemic lupus erythematosus (SLE) antibodies - Sep., p. 260
T-20 - Oct., p. 300
T30177 - Mar., p. 75
TA-GW HPV vaccine - Oct., p. 301
Taq DNA polymerase - Feb., p. 45
Theradigm - Oct., p. 300; Nov., p. 330
thiacytidine, (-)2',3'-dideoxy-3'- (use 3TC)
thymosin alpha 1 - Feb., p. 41; June, p. 171; Nov., p. 331
TLC A-60 - Apr., p. 109
TRAx CD4 Test Kit - July, p. 204
triple helix oligonucleotides - Mar., p. 75
U-103,017 - Mar., p. 72
universal T-cell transplants - Nov., p. 328
vaccine adjuvants - July, p. 200; Sep., p. 270; Oct., p. 299, 302
vaccines, T-cell activation - Dec., p. 363
valacyclovir hydrochloride - Apr., p. 101; Aug., p. 225; Dec., p. 356
Valtrex (use valacyclovir hydrochloride)
Vaqta - May, p. 129; Aug., p. 236
Varicella Virus Vaccine Live - Mar., p. 65; Apr., p. 104; July, p. 204
Venezuelan equine encephalitis vaccines - July, p. 205
Videx (use DDI)
VIMRxyn (use hypericin)
Viracept (use AG1343)
viral inactivation, blood products - Nov., p. 331
Viralex - Apr., p. 105
Virazole (use ribavirin)
VISTIDE (use cidofovir)
Vitrasert Implant (use ganciclovir, implant)
VX-478 - Mar., p. 72; May, p. 140; Aug., p. 233; Dec., p. 356
xenotransplantation - May, p. 140; Aug., p. 230
ZADAXIN (use thymosin alpha 1)
Zerit (use D4T)
zidovudine (use AZT)
Zovirax (use acyclovir)
Zyn-Linker oligonucleotide derivatives - Dec., p. 364